Education
About Us
Working with TipRanks
Follow Us
Lipigon Pharmaceuticals AB (DE:9RP)
:9RP
9RP Stock Chart & Stats
Day’s Range― - ―
52-Week Range<€0.01 - €0.03
Previous CloseN/A
Volume0.00
Average Volume (3M)3.70K
Market Cap
€1.25M
Enterprise Value€26.87M
Total Cash (Recent Filing)-kr2.49M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta73.41
Next Earnings
May 27, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding126,422,280
10 Day Avg. Volume0
30 Day Avg. Volume3,703
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)8.75
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
9RP FAQ
What was Lipigon Pharmaceuticals AB’s price range in the past 12 months?
Lipigon Pharmaceuticals AB lowest stock price was <€0.01 and its highest was €0.03 in the past 12 months.
What is Lipigon Pharmaceuticals AB’s market cap?
Lipigon Pharmaceuticals AB’s market cap is €1.25M.
When is Lipigon Pharmaceuticals AB’s upcoming earnings report date?
Lipigon Pharmaceuticals AB’s upcoming earnings report date is May 27, 2025 which is in 30 days.
How were Lipigon Pharmaceuticals AB’s earnings last quarter?
Lipigon Pharmaceuticals AB released its earnings results on Feb 19, 2025. The company reported -€0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.007.
Is Lipigon Pharmaceuticals AB overvalued?
According to Wall Street analysts Lipigon Pharmaceuticals AB’s price is currently Overvalued.
Does Lipigon Pharmaceuticals AB pay dividends?
Lipigon Pharmaceuticals AB does not currently pay dividends.
What is Lipigon Pharmaceuticals AB’s EPS estimate?
Lipigon Pharmaceuticals AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lipigon Pharmaceuticals AB have?
Lipigon Pharmaceuticals AB has 126,422,280 shares outstanding.
What happened to Lipigon Pharmaceuticals AB’s price movement after its last earnings report?
Lipigon Pharmaceuticals AB reported an EPS of -€0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Lipigon Pharmaceuticals AB?
Currently, no hedge funds are holding shares in DE:9RP
---
Company Description
Lipigon Pharmaceuticals AB
Lipigon Pharmaceuticals AB develops medicines for diseases caused by disorders of the body's handling of fats. It focuses on orphan drugs for unusual diseases where there is no adequate treatment.
---
Technical Analysis
LIDDS AB
―
Scandion Oncology A/S
―
Spago Nanomedical AB
―
CombiGene AB
―
QuiaPEG Pharmaceuticals Holding AB
―
---